Home
HelpTest Code MAGE4 Melanoma-Associated Antigen-A4 (MAGE-A4), Semi-Quantitative Immunohistochemistry, Manual
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
A pathology/diagnostic report and a brief history are required.
Specimen Required
Specimen Type: Tissue
Supplies: Pathology Packaging Kit (T554)
Submit:
Formalin-fixed, paraffin-embedded tissue block
OR
3 Unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information:
1. One slide will be stained with hematoxylin and eosin and returned.
2. Broken or cracked unstained slides will be rejected. Stained slides that were broken and repaired (ie, double mounted) at the client site will not be rejected, as, in most cases, they can still be reviewed under the microscope. However, due to the double mounting, digital scanning cannot be performed.
Useful For
Determining expression of melanoma-associated antigen-A4 (MAGE-A4) in synovial sarcoma and other neoplasms
As an aid in screening patients who may be eligible for TECELRA (afamitresgene autoleucel) therapy
Method Name
Immunohistochemistry (IHC)
Reporting Name
MAGE-A4, SemiQuant IHC, ManualSpecimen Type
SpecialSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Special | Ambient (preferred) | |
| Refrigerated | ||
Reference Values
An interpretive report will be provided.
Interpretation
Melanoma-associated antigen-A4 (MAGE-A4) in synovial sarcomas is determined positive when there is at least moderate to strong cytoplasmic and/or nuclear staining in greater than or equal to 75% of tumor cells.(1)
This result should be interpreted in the appropriate clinical context.
Clinical Reference
1. Instruction manual: MAGE-A4 IHC 1F9 pharmDx Interpretation Manual-Synovial Sarcoma. Agilent Technologies, Inc; 08/29/2024
2. Caballero O, Chen Y. Cancer/testis (CT) antigens Potential targets for immunotherapy. Cancer Science 2009;100(11):2014-2021
3. Hong D, Van Tine B, Biswas S, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients a phase 1 trial. Nature Medicine 2023;29:104-114
4. Wang T, Navenot JM, Rafail S, et al. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A*02-eligible patients. Mol Ther Methods Clin Dev. 2024;32(2):101265. Published 2024 May 14. doi:10.1016/j.omtm.2024.101265
Day(s) Performed
Monday through Friday
Report Available
5 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88360
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MAGE4 | MAGE-A4, SemiQuant IHC, Manual | 111581-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 622998 | Interpretation | 59465-5 |
| 622999 | Participated in the Interpretation | No LOINC Needed |
| 623000 | Report electronically signed by | 19139-5 |
| 623001 | Material Received | 81178-6 |
| 623002 | Disclaimer | 62364-5 |
| 623003 | Case Number | 80398-1 |
Forms
If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.